VPM-1002 is under clinical development by Serum Institute of India and currently in Phase III for Pulmonary Tuberculosis. According to GlobalData, Phase III drugs for Pulmonary Tuberculosis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how VPM-1002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Serum Institute of India overview
Serum Institute of India (Serum Institute), a subsidiary of Cyrus Poonawalla Group, is a biotechnology company that manufactures and supplies vaccines and immuno-biologicals to treat polio, diphtheria, tetanus, pertussis, r-hepatitis B, measles, mumps and rubella. The company’s product portfolio includes bacterial, viral, covid, influenza, polysaccharide conjugate and combination vaccines; recombinant and pharma products; and anti-sera vaccines. It markets the Oxford–AstraZeneca COVID-19 vaccine under the brand name Covishield in India. It is investigating DTaP, an acellular vaccine against pertussis; pentavalent meningococcal conjugate vaccine to prevent epidemic group A meningococcal disease; ErepoXen, to maintain red blood cell production and prevent anemia caused by chronic kidney failure; and HPV vaccine against cervical cancer. Serum Institute is headquartered in Pune, Maharashtra, India
For a complete picture of VPM-1002’s drug-specific PTSR and LoA scores, buy the report here.